BioConnection returns 20,000 euros at symbolic conclusion of employment project
Pharmaceutical company BioConnection returned a check containing 20,000 euros of MSD money on Thursday, March 31. That symbolic step marks the provisional end of a program that was intended to boost employment in Oss.
PPSC and CeMOS have formed a strategic partnership to provide industry-leading joint early drug discovery services, with an emphasis on label-free “cell-based” target-centric, phenotypic, and functional MALDI MS assays for ultra-High-Throughput Screening (uHTS), hit-to-lead biological profiling and in-vitro DMPK/ADME-T.
Preclinical Drug Discovery in just 5 days
After the success of last year, Radboud University has selected life sciences campus, Pivot Park in Oss, as the backdrop of one of their summer school courses in July 2022. Radboud University teamed up with Pivot Park Screening Centre, and HAN University of Applied Science to organize the summer school course: Introduction to preclinical drug discovery.
Sustainability at Pivot Park – replacement paper coffee cups
In 2020, we developed a strategic vision (Pivot Park Sustainability Report 2021-2026) of the opportunities and ambitions we can and could have regarding sustainability going forward. One of the short-term contributions we wanted to make is to replace the paper coffee cups.
Pivot Park viert deze week het tienjarig bestaan. Maar het mooiste ‘cadeau’ wordt pas in september 2023 uitgepakt: het grote gebouw Grizzly. Welke vijf bedrijven trekken daar in? Een voorstelrondje.
Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs
Synaffix announced their second deal of 2022 with MacroGenics, Inc. with a potential deal value of up to $586 million, plus royalties on commercial sales.
MacroGenics will combine its proprietary antibody and bispecific DART® technology with their linker-payload technologies to develop up to three next generation both monospecific and bispecific conjugates.
Pharming Group announces positive results from the pivotal Phase II/III blinded randomized, placebo-controlled registration-enabling study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) also known as PASLI (p110δ-activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency).
Pivot Park viert tienjarig bestaan
De vlag kan uit op Pivot Park. Op 1 februari is het namelijk precies tien jaar geleden dat de Osse Life Sciences park zijn levenslicht zag. In die periode heeft het bedrijvenpark zich ontwikkeld tot een biofarmaceutische hotspot. Om het jubileum te vieren, staat Pivot Park in 2022 stil bij zijn successen en kijkt het uit naar de toekomst.
“We are very excited to advance our ambitions driving our valuable innovation-driven antibody discovery, selection, engineering, and manufacturing capabilities in our new state-of-the-art facility. We are confident that this expansion enables us to meet the growing interest in IPA’s custom antibody solutions and R&D activities.”
Ardena expands capacity to satisfy Novavax COVID vaccine demand
Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO), announced it will be expanding its capacity for purification and fractionation of GMP manufacturing at its site in Södertälje, Sweden.
Genmab and Synaffix Enter into License Agreement for ADC Technology
Genmab A/S (Nasdaq: GMAB) and Synaffix B.V., announced today that Genmab and Synaffix have signed a license agreement providing Genmab broad access to Synaffix’s ADC technologies.
Pivot Park klaar voor de start van bouw Grizzly
Persbericht: Oss, 24 december Duurzaam life sciences-gebouw al grotendeels verhuurd Pivot Park klaar voor de start van bouw Grizzly
Pivot Park –
Gebouw RK
Kloosterstraat 9
5349 AB Oss
the Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Gebouw OP
Kloosterstraat 9
5349AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.
